Inhaled human insulin ((insulin human [rDNA origin]) Inhalation Powder) in diabetes mellitus.
Inhaled human insulin ((insulin human [rDNA origin]) Inhalation Powder) is a prandial insulin approved in the EU and the US for the treatment of adults with diabetes. Its glycaemic control is comparable to subcutaneous insulin in Type 1 and 2 diabetes, and has superior efficacy versus oral antidiabetic agents in Type 2 diabetes. Hypoglycaemia and mild-to-moderate cough are the main side effects. The treatment group differences in pulmonary function occur early, and are small, nonprogressive for up to 2 years and reversible following discontinuation. Patient-reported outcomes data displays higher diabetes treatment satisfaction, improvements in some quality-of-life scores, and treatment preference with inhaled human insulin versus traditional means. Availability of inhaled insulin may increase insulin acceptance and thus improve glycaemic control in patients with diabetes.
Mathieu
Chantal
C
UZ Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium. chantal.mathieu@med.kuleuven.ac.be
D000280:Administration, Inhalation; D002986:Clinical Trials as Topic; D004275:DNA, Ribosomal; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011208:Powders
D004275:DNA, Ribosomal; C473734:Exubera; D007004:Hypoglycemic Agents; D007328:Insulin; D011208:Powders